HIV AND CANCER: ARE THEY RELATED?

Chaterina Janes Pratiwi

doi:10.29082/IJNMS/2025/Vol9/Iss3/805

Authors

Chaterina Janes Pratiwi Universitas Bina Sehat PPNI

DOI:

https://doi.org/10.29082/IJNMS/2025/Vol9/Iss3/805

Keywords:

HIV, Cancer after HIV, NADC

Abstract

People living with HIV (PLHIV) are at higher risk of developing various types of cancer and viral infections compared to the general population. Cancers after diagnosis HIV (AIDS-defining cancers) include Kaposi's sarcoma, cervical cancer, and lymphoma. However, cancer can be various types of cancer, it's called non-AIDS defining cancers (NADC). The aim of this study was to identify the relatedness between cancer and HIV and estimate the timeframe for the onset of cancer symptoms after HIV infection. The descriptive analysis method involved 23 respondents with HIV and cancer. The study results showed NADC: breast cancer, liver cancer, leukemia, brain cancer, nasopharyngeal cancer, colon cancer, and rectal cancer. Whereas, HIV-related cancers included cervical cancer and lymphoma. The average time to cancer diagnosis after HIV was 2.73 years, with a standard deviation of 3.06 years, indicating large range of variation in each respondent. The confidence interval of 1.41-4.06 years means a high time difference between respondents. The earliest time to cancer symptoms in HIV was 0.6 years, and the longest time was 14.6 years. Timeframe for cancer to appear after HIV diagnosis is influenced by severe immunodeficiency, as indicated by decreased CD4 counts, age, opportunistic infections, genetic history of cancer, and cancer type. It is important to have self-awareness about early cervical cancer screening for HIV-positive women and regulations that integrate cancer screening services into HIV service units.

Downloads

Download data is not yet available.

References

Agaba, C. D., Namuli, A., Ainomugisha, B., Tibaijuka, L., Ninsiima, M., Ngonzi, J., Akatukwasa, C., & Owaraganise, A. (2024). Providers and women's perspectives on opportunities, challenges and recommendations to improve cervical cancer screening in women living with HIV at Mbarara Regional Referral Hospital: a qualitative study. BMC women's health, 24(1), 392. https://doi.org/10.1186/s12905-024-03239-0

Ashindoitiang, J. A., Nwagbara, V. I. C., Ozinko, M. O., Ugbem, T. I., & Asuquo, M. E. (2024). Multiple carcinomas in a woman with HIV infection: a case report and literature review. The Journal of international medical research, 52(4), 3000605241245011. https://doi.org/10.1177/03000605241245011

Beumer, J. H., Venkataramanan, R., & Rudek, M. A. (2014). Pharmacotherapy in cancer patients with HIV/AIDS. Clinical pharmacology and therapeutics, 95(4), 370–372. https://doi.org/10.1038/clpt.2014.10

Bonnet, F., Lewden, C., May, T., Heripret, L., Jougla, E., Bevilacqua, S., Costagliola, D., Salmon, D., Chêne, G., & Morlat, P. (2004). Malignancy-related causes of death in human immunodeficiency virus-infected patients in the era of highly active antiretroviral therapy. Cancer, 101(2), 317–324. https://doi.org/10.1002/cncr.20354

Chen, L., Feng, Z., Yue, H., Bazdar, D., Mbonye, U., Zender, C., Harding, C. V., Bruggeman, L., Karn, J., Sieg, S. F., Wang, B., & Jin, G. (2018). Exosomes derived from HIV-1-infected cells promote growth and progression of cancer via HIV TAR RNA. Nature communications, 9(1), 4585. https://doi.org/10.1038/s41467-018-07006-2

Chiao, E. Y., Coghill, A., Kizub, D., Fink, V., Ndlovu, N., Mazul, A., & Sigel, K. (2021). The effect of non-AIDS-defining cancers on people living with HIV. The Lancet. Oncology, 22(6), e240–e253. https://doi.org/10.1016/S1470-2045(21)00137-6

Cooper, E. H., & Lacey, C. J. (1988). Laboratory indices of prognosis in HIV infection. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 42(8), 539–545.

Dunne, E. M., Rosen, R. K., McTigue, G. L., Jamison, R. N., Yeh, G. Y., Rich, J. D., & Carey, M. P. (2022). The Lived Experience of Managing HIV and Chronic Pain: Qualitative Interviews with Patients and Healthcare Providers. AIDS and behavior, 26(2), 496–511. https://doi.org/10.1007/s10461-021-03406-6

Engels, E. A., Shiels, M. S., Barnabas, R. V., Bohlius, J., Brennan, P., Castilho, J., Chanock, S. J., Clarke, M. A., Coghill, A. E., Combes, J. D., Dryden-Peterson, S., D'Souza, G., Gopal, S., Jaquet, A., Lurain, K., Makinson, A., Martin, J., Muchengeti, M., Newton, R., Okuku, F., … Clifford, G. M. (2024). State of the science and future directions for research on HIV and cancer: Summary of a joint workshop sponsored by IARC and NCI. International journal of cancer, 154(4), 596–606. https://doi.org/10.1002/ijc.34727

Ibrahim Khalil, A., Mpunga, T., Wei, F., Baussano, I., de Martel, C., Bray, F., Stelzle, D., Dryden-Peterson, S., Jaquet, A., Horner, M. J., Awolude, O. A., Trejo, M. J., Mudini, W., Soliman, A. S., Sengayi-Muchengeti, M., Coghill, A. E., van Aardt, M. C., De Vuyst, H., Hawes, S. E., Broutet, N., … Clifford, G. M. (2022). Age-specific burden of cervical cancer associated with HIV: A global analysis with a focus on sub-Saharan Africa. International journal of cancer, 150(5), 761–772. https://doi.org/10.1002/ijc.33841

lLewis, S., Mphande, M., Chibwana, F., Gumbo, T., Banda, B. A., Sigauke, H., Moses, A., Gupta, S., Hoffman, R. M., & Moucheraud, C. (2022). Association of HIV status and treatment characteristics with VIA screening outcomes in Malawi: A retrospective analysis. PloS one, 17(1), e0262904. https://doi.org/10.1371/journal.pone.0262904

Lim, S. T., & Levine, A. M. (2005). Non-AIDS-defining cancers and HIV infection. Current HIV/AIDS reports, 2(3), 146–153. https://doi.org/10.1007/s11904-005-0008-4

Mallela, A., Lenhart, S., & Vaidya, N. K. (2016). HIV–TB co-infection treatment: Modeling and optimal control theory perspectives. Journal of Computational and Applied Mathematics, 307, 143-161. doi:10.1016/j.cam.2016.02.051

Means, A. R., Risher, K. A., Ujeneza, E. L., Maposa, I., Nondi, J., & Bellan, S. E. (2016). Impact of Age and Sex on CD4+ Cell Count Trajectories following Treatment Initiation: An Analysis of the Tanzanian HIV Treatment Database. PloS one, 11(10), e0164148. https://doi.org/10.1371/journal.pone.0164148

Parrish, M., Traugh, N., Seraj, M., & Kuperwasser, C. (2025). Field cancerization, accelerated aging, and immunosuppression: the rapid rise of hormone-sensitive and early-onset breast cancer. NPJ breast cancer, 11(1), 128. https://doi.org/10.1038/s41523-025-00840-w

Quinn, G. P., Sanchez, J. A., Sutton, S. K., Vadaparampil, S. T., Nguyen, G. T., Green, B. L., . . . Schabath, M. B. (2015). Cancer and lesbian, gay, bisexual, transgender/transsexual, and queer/questioning (LGBTQ) populations. CA: A Cancer Journal for Clinicians, 65(5), 384-400. doi:10.3322/caac.21288

Simard, E. P., Pfeiffer, R. M., & Engels, E. A. (2011). Cumulative incidence of cancer among individuals with acquired immunodeficiency syndrome in the United States. Cancer, 117(5), 1089–1096. https://doi.org/10.1002/cncr.25547

Souza, T. F., Sym, Y. V., & Chehter, E. Z. (2023). HIV and neoplasms: What do we know so far?. Einstein (Sao Paulo, Brazil), 21, eRW0231. https://doi.org/10.31744/einstein_journal/2023RW0231

Suárez-García, I., Gutierrez, F., Pérez-Molina, J. A., Moreno, S., Aldamiz, T., Valencia Ortega, E., Curran, A., Gutiérrez González, S., Asensi, V., Amador Prous, C., Jarrin, I., Rava, M., & CoRIS (2023). Mortality due to non-AIDS-defining cancers among people living with HIV in Spain over 18 years of follow-up. Journal of cancer research and clinical oncology, 149(20), 18161–18171. https://doi.org/10.1007/s00432-023-05500-9

Taylor, J. M., Fahey, J. L., Detels, R., & Giorgi, J. V. (1989). CD4 percentage, CD4 number, and CD4:CD8 ratio in HIV infection: which to choose and how to use. Journal of acquired immune deficiency syndromes, 2(2), 114–124.